Exabis Library
Welcome to the e-CCO Library!
P667: Unmet needs in the management of Inflammatory Bowel Diseases in Egypt
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P667: USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn's Disease– results from STEADY study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P668: Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResource
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P668: Does biotin deficiency play a role in the pathogenesis of Inflammatory Bowel Disease? Preliminary results of a cross-sectional study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P668: Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P668: Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P668: Real world use and adverse events of SARs-CoV-2 vaccination in Greek patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P669: Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P669: Effect of vedolizumab therapy on whole blood transcriptional profiles in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P669: Human β-defensin 2 suppresses TNF-α secretion in human and mouse dendritic cells mediated by chemokine receptor-2
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P669: Improving Crohn's disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P669: Validation of prior infliximab exposure and total colectomy outcome in patients with ulcerative colitis in Sweden
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P670: Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P670: Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care population
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P670: Familial Inflammatory Bowel Disease is associated with a more adverse disease compared to sporadic cases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM